(TAK) Takeda Pharmaceutical - Ratings and Ratios
Exchange: NYSE •
Country: Japan •
Currency: USD •
Type: Common Stock •
ISIN: US8740602052
Oncology, Gastroenterology, Immunology, Rare Diseases, Plasma Therapies
Dividends
| Dividend Yield | 4.63% |
| Yield on Cost 5y | 4.35% |
| Yield CAGR 5y | -2.45% |
| Payout Consistency | 91.9% |
| Payout Ratio | 0.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 17.9% |
| Value at Risk 5%th | 29.2% |
| Relative Tail Risk | -0.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | 1.69 |
| CAGR/Max DD | 0.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.492 |
| Beta | 0.225 |
| Beta Downside | 0.165 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.25% |
| Mean DD | 10.10% |
| Median DD | 10.03% |
Description: TAK Takeda Pharmaceutical December 04, 2025
Takeda Pharmaceutical Co. (NYSE:TAK) is a global, Japan-based drug developer that conducts R&D, manufacturing, marketing, and out-licensing across a broad therapeutic portfolio-including gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Its commercial brands span Entyvio, Velcade, Adcetris, and many others, while the firm maintains an extensive network of in-license, collaboration, and licensing agreements with partners such as BioMarin, GSK, Seagen, and Arrowhead to broaden its pipeline.
Key recent metrics: FY2023 revenue was roughly $30 billion, with R&D spending representing about 10 % of sales, reflecting a continued focus on high-margin specialty drugs. The gastrointestinal franchise (Entyvio) and the oncology pipeline (e.g., Adcetris, Iclusig) are the primary growth engines, together accounting for > 30 % of net sales. A sector-wide driver is the aging population in Japan and the U.S., which is expanding demand for rare-disease and biologic therapies-segments where Takeda holds a competitive advantage.
For a deeper dive into Takeda’s valuation metrics and peer comparison, you may find the ValueRay platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (33.03b TTM) > 0 and > 6% of Revenue (6% = 265.02b TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 2.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.68% (prev 14.67%; Δ 3.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 1199.57b > Net Income 33.03b (YES >=105%, WARN >=100%) |
| Net Debt (3963.83b) to EBITDA (1130.17b) ratio: 3.51 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.15b) change vs 12m ago -2.02% (target <= -2.0% for YES) |
| Gross Margin 64.60% (prev 65.95%; Δ -1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.42% (prev 31.20%; Δ -0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.50 (EBITDA TTM 1130.17b / Interest Expense TTM 244.32b) >= 6 (WARN >= 3) |
Altman Z'' 1.19
| (A) 0.05 = (Total Current Assets 2920.62b - Total Current Liabilities 2139.66b) / Total Assets 14470.30b |
| (B) 0.08 = Retained Earnings (Balance) 1148.66b / Total Assets 14470.30b |
| (C) 0.03 = EBIT TTM 366.65b / Avg Total Assets 14521.65b |
| (D) 0.39 = Book Value of Equity 2839.82b / Total Liabilities 7338.61b |
| Total Rating: 1.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.04
| 1. Piotroski 3.50pt |
| 2. FCF Yield 8.69% |
| 3. FCF Margin 22.14% |
| 4. Debt/Equity 0.65 |
| 5. Debt/Ebitda 3.51 |
| 6. ROIC - WACC (= -1.03)% |
| 7. RoE 0.47% |
| 8. Rev. Trend 76.73% |
| 9. EPS Trend 3.53% |
What is the price of TAK shares?
As of December 10, 2025, the stock is trading at USD 14.26 with a total of 1,588,133 shares traded.
Over the past week, the price has changed by -0.21%, over one month by +4.01%, over three months by -4.52% and over the past year by +8.56%.
Over the past week, the price has changed by -0.21%, over one month by +4.01%, over three months by -4.52% and over the past year by +8.56%.
Is TAK a buy, sell or hold?
Takeda Pharmaceutical has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy TAK.
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TAK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.4 | 22% |
| Analysts Target Price | 17.4 | 22% |
| ValueRay Target Price | 15.1 | 5.6% |
TAK Fundamental Data Overview November 26, 2025
Market Cap JPY = 7352.01b (47.32b USD * 155.3659 USD.JPY)
P/E Trailing = 203.1429
P/E Forward = 9.5602
P/S = 0.0107
P/B = 0.9948
P/EG = 0.2978
Beta = 0.028
Revenue TTM = 4417.01b JPY
EBIT TTM = 366.65b JPY
EBITDA TTM = 1130.17b JPY
Long Term Debt = 4351.46b JPY (from longTermDebt, last quarter)
Short Term Debt = 293.86b JPY (from shortTermDebt, last quarter)
Debt = 4645.32b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 3963.83b JPY (from netDebt column, last quarter)
Enterprise Value = 11257.65b JPY (7352.01b + Debt 4645.32b - CCE 739.68b)
Interest Coverage Ratio = 1.50 (Ebit TTM 366.65b / Interest Expense TTM 244.32b)
FCF Yield = 8.69% (FCF TTM 977.79b / Enterprise Value 11257.65b)
FCF Margin = 22.14% (FCF TTM 977.79b / Revenue TTM 4417.01b)
Net Margin = 0.75% (Net Income TTM 33.03b / Revenue TTM 4417.01b)
Gross Margin = 64.60% ((Revenue TTM 4417.01b - Cost of Revenue TTM 1563.71b) / Revenue TTM)
Gross Margin QoQ = 65.85% (prev 65.24%)
Tobins Q-Ratio = 0.78 (Enterprise Value 11257.65b / Total Assets 14470.30b)
Interest Expense / Debt = 1.79% (Interest Expense 83.14b / Debt 4645.32b)
Taxrate = 141.6% (out of range, set to none) (39.90b / 28.17b)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.36 (Total Current Assets 2920.62b / Total Current Liabilities 2139.66b)
Debt / Equity = 0.65 (Debt 4645.32b / totalStockholderEquity, last quarter 7130.70b)
Debt / EBITDA = 3.51 (Net Debt 3963.83b / EBITDA 1130.17b)
Debt / FCF = 4.05 (Net Debt 3963.83b / FCF TTM 977.79b)
Total Stockholder Equity = 7087.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.23% (Net Income 33.03b / Total Assets 14470.30b)
RoE = 0.47% (Net Income TTM 33.03b / Total Stockholder Equity 7087.33b)
RoCE = 3.21% (EBIT 366.65b / Capital Employed (Equity 7087.33b + L.T.Debt 4351.46b))
RoIC = 3.16% (EBIT 366.65b / (Assets 14470.30b - Curr.Liab 2139.66b - Cash 739.68b))
WACC = 4.19% (E(7352.01b)/V(11997.33b) * Re(6.84%) + (debt cost/tax rate unavailable))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.24%
[DCF Debug] Terminal Value 75.80% ; FCFE base≈845.77b ; Y1≈723.96b ; Y5≈562.74b
Fair Price DCF = 3255 (DCF Value 10282.25b / Shares Outstanding 3.16b; 5y FCF grow -17.51% → 3.0% )
EPS Correlation: 3.53 | EPS CAGR: -0.32% | SUE: -0.00 | # QB: 0
Revenue Correlation: 76.73 | Revenue CAGR: 5.78% | SUE: -0.04 | # QB: 0
EPS current Year (2026-03-31): EPS=73.97 | Chg30d=-0.590 | Revisions Net=-1 | Growth EPS=+117.6% | Growth Revenue=+673.7%
EPS next Year (2027-03-31): EPS=122.17 | Chg30d=-0.974 | Revisions Net=-1 | Growth EPS=+65.2% | Growth Revenue=+1.1%
P/E Trailing = 203.1429
P/E Forward = 9.5602
P/S = 0.0107
P/B = 0.9948
P/EG = 0.2978
Beta = 0.028
Revenue TTM = 4417.01b JPY
EBIT TTM = 366.65b JPY
EBITDA TTM = 1130.17b JPY
Long Term Debt = 4351.46b JPY (from longTermDebt, last quarter)
Short Term Debt = 293.86b JPY (from shortTermDebt, last quarter)
Debt = 4645.32b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 3963.83b JPY (from netDebt column, last quarter)
Enterprise Value = 11257.65b JPY (7352.01b + Debt 4645.32b - CCE 739.68b)
Interest Coverage Ratio = 1.50 (Ebit TTM 366.65b / Interest Expense TTM 244.32b)
FCF Yield = 8.69% (FCF TTM 977.79b / Enterprise Value 11257.65b)
FCF Margin = 22.14% (FCF TTM 977.79b / Revenue TTM 4417.01b)
Net Margin = 0.75% (Net Income TTM 33.03b / Revenue TTM 4417.01b)
Gross Margin = 64.60% ((Revenue TTM 4417.01b - Cost of Revenue TTM 1563.71b) / Revenue TTM)
Gross Margin QoQ = 65.85% (prev 65.24%)
Tobins Q-Ratio = 0.78 (Enterprise Value 11257.65b / Total Assets 14470.30b)
Interest Expense / Debt = 1.79% (Interest Expense 83.14b / Debt 4645.32b)
Taxrate = 141.6% (out of range, set to none) (39.90b / 28.17b)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.36 (Total Current Assets 2920.62b / Total Current Liabilities 2139.66b)
Debt / Equity = 0.65 (Debt 4645.32b / totalStockholderEquity, last quarter 7130.70b)
Debt / EBITDA = 3.51 (Net Debt 3963.83b / EBITDA 1130.17b)
Debt / FCF = 4.05 (Net Debt 3963.83b / FCF TTM 977.79b)
Total Stockholder Equity = 7087.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.23% (Net Income 33.03b / Total Assets 14470.30b)
RoE = 0.47% (Net Income TTM 33.03b / Total Stockholder Equity 7087.33b)
RoCE = 3.21% (EBIT 366.65b / Capital Employed (Equity 7087.33b + L.T.Debt 4351.46b))
RoIC = 3.16% (EBIT 366.65b / (Assets 14470.30b - Curr.Liab 2139.66b - Cash 739.68b))
WACC = 4.19% (E(7352.01b)/V(11997.33b) * Re(6.84%) + (debt cost/tax rate unavailable))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.24%
[DCF Debug] Terminal Value 75.80% ; FCFE base≈845.77b ; Y1≈723.96b ; Y5≈562.74b
Fair Price DCF = 3255 (DCF Value 10282.25b / Shares Outstanding 3.16b; 5y FCF grow -17.51% → 3.0% )
EPS Correlation: 3.53 | EPS CAGR: -0.32% | SUE: -0.00 | # QB: 0
Revenue Correlation: 76.73 | Revenue CAGR: 5.78% | SUE: -0.04 | # QB: 0
EPS current Year (2026-03-31): EPS=73.97 | Chg30d=-0.590 | Revisions Net=-1 | Growth EPS=+117.6% | Growth Revenue=+673.7%
EPS next Year (2027-03-31): EPS=122.17 | Chg30d=-0.974 | Revisions Net=-1 | Growth EPS=+65.2% | Growth Revenue=+1.1%
Additional Sources for TAK Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle